Navigation Links
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
Date:3/13/2008

VANCOUVER, March 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced today that it has entered into a definitive licensing agreement with privately held Rex Medical, LP ("Rex Medical") for exclusive worldwide rights to market and distribute the Option(TM) inferior vena cava (IVC) filter, a medical device that is implanted into the body's inferior vena cava to prevent pulmonary embolism (PE).

According to industry research, the U.S. market for IVC filters in 2007 was approximately $200 million with retrievable filters accounting for approximately two-thirds of this market. The Option(TM) IVC filter, developed by Rex Medical, is an IVC filter specifically designed for long-term retrieval post device implantation and is expected to be approved for both permanent and retrievable indications.

Angiotech and Rex Medical will be exhibiting at the 33rd Annual Meeting of the Society of Interventional Radiology (SIR) to be held in Washington, DC from March 15-18, 2008.

"With product offerings such as the Option(TM) IVC filter and our EnSnare(TM) retrieval device, we are continuing our commitment to offer industry-leading technologies to service the needs of our interventional and endovascular call points. We believe that the Option(TM) IVC filter is a cornerstone technology for our Interventional business and a 'best-in-class' product that will be significantly differentiated in the marketplace," said Dr. William Hunter, President and CEO of Angiotech.

"We are pleased to have entered into this commercial partnership with Angiotech for the Option(TM) IVC filter in such a critical market for the interventional community. We believe that the Option(TM) IVC filter is a superior IVC f
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
2. Angiotech announces results for the fourth quarter ended December 31, 2007
3. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
5. Angiotech and Symphony Medical Announce Licensing Agreement
6. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
7. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
8. Angiotech to participate in RBC 2007 Healthcare Conference
9. Angiotech to participate in Bank of America 2007 Credit Conference
10. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
11. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... shares of its Common Stock and Series A Convertible ... The Series A Convertible Preferred Stock is non-voting and ... conversion will be prohibited if, as a result, the ... 4.99% of the Common Stock then outstanding. As part ...
(Date:9/17/2014)... Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... of another peer-reviewed clinical study.    ... Randomized Controlled Clinical Trial Evaluating the Use of ... and Multi-layer Compression Therapy vs. Multi-layer Compression Therapy ...
(Date:9/17/2014)... & Rockville, MD (PRWEB) September 17, 2014 ... a Small Business Innovation Research (SBIR) grant to support ... The award will provide ITI with approximately $255,000 over ... nuts, a leading cause of food allergy, affect over ... of anaphylaxis behind peanut allergy. Tree nut exposure is ...
(Date:9/17/2014)... 17, 2014 Alternative Fuels Americas, Inc. (AFAI) announced ... Special Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... company. The SPV shall be called AFAI Jatro Green Ethiopia ... majority shareholder. The SPV shall pursue Jatropha planting and biofuels ... Ethiopia . "Although we have ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... is pleased to announce that they have acquired ... fully diluted basis. The cash consideration,will be used ... further develop,its technology., Molecular Vision is developing ... that will greatly extend the in-house tools,available to ...
... Inc.,(Nasdaq: VTIV ) today announced that Eran ... Officer, will make a presentation at the,2008 UBS ... which will,be held February 11-13, 2008. The conference ... management presentations and,extensive Q&A opportunities., inVentiv,s presentation ...
... loss of some top,talent, including Lipitor pioneer Dr. ... teaming to help speed research to fight bone ... arthritis and,osteoporosis., Velcura Therapeutics President and CEO ... work with Dr. Sliskovic and International,Discovery Sourcing Consultants, ...
Cached Biology Technology:Acrongenomics Acquires Equity Stake in Molecular Vision 2Acrongenomics Acquires Equity Stake in Molecular Vision 3inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2
(Date:9/17/2014)... Kingdom forms a new crime unit designed to fight ... year over horse meat being passed off as beef ... detecting meat adulteration. They describe their approach, which represents ... Journal of Agricultural and Food Chemistry . , Hans-Ulrich ... major global economic problem. But they also say that ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... University doctoral candidate and a National Park Service researcher ... , J. Judson "Jut" Wynne, an NAU graduate student ... Biological Science Center, and Kyle Voyles from Parashant National ... in northwestern Arizona. , The still-unnamed genus of cave ...
... living on mineral water, the glassy-winged sharpshooter consumes only ... which is feverishly working to prevent the insect's flight ... study published in the June 6 issue of Public ... Institute for Genomic Research (TIGR), the University of Arizona, ...
... approaches to genetic disease, based on cells' own ability to ... at the annual conference of the European Society of Human ... Instead of replacing a faulty gene (commonly referred to as ... therapeutic potential that already exists in human biology. , Professor ...
Cached Biology News:NAU researchers chirping over discovery of new cricket genus 2NAU researchers chirping over discovery of new cricket genus 3Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4
... This personal-sized Thermal Cycler is the ideal ... a full range of PCR applications. ... affordable price. Save lab space without ... software. Industry-Standard PCR Technology You Can ...
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: